Literature DB >> 6337171

Compliance with disulfiram treatment of alcoholism.

R Fuller, H Roth, S Long.   

Abstract

One hundred twenty-four men were randomly assigned to receive disulfiram with a riboflavin marker or riboflavin alone. During a one year follow-up urine specimens were collected at each visit and analyzed for riboflavin. There was a strong relationship between excellent attendance and infrequent drinking. For subjects taking disulfiram there was a high correlation between a subject submitting 15 or more positive urines during follow-up and infrequent drinking. For the disulfiram patients there was also a strong relationship between continuous usage of disulfiram and infrequent drinking. However, the correlation between percentage of urine specimens positive for the riboflavin marker and infrequent drinking was slight. This occurred because a person who was drinking tended to return for follow-up only when he was not drinking and thus submitted only a few specimens of which the majority were positive. We conclude that (1) excellent attendance, (2) submission of a large number of positive urines and (3) a period of continuous compliance to the disulfiram regimen were highly associated with infrequent drinking.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6337171     DOI: 10.1016/0021-9681(83)90090-5

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN: 0021-9681


  4 in total

1.  Riboflavin as an oral tracer for monitoring compliance in clinical research.

Authors:  V M Sadagopa Ramanujam; Karl E Anderson; James J Grady; Fatima Nayeem; Lee-Jane W Lu
Journal:  Open Biomark J       Date:  2011

2.  Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram.

Authors:  Ismene L Petrakis; Charla Nich; Elizabeth Ralevski
Journal:  Schizophr Bull       Date:  2006-08-03       Impact factor: 9.306

3.  The Cochrane Lecture. The best and the enemy of the good: randomised controlled trials, uncertainty, and assessing the role of patient choice in medical decision making.

Authors:  K McPherson
Journal:  J Epidemiol Community Health       Date:  1994-02       Impact factor: 3.710

Review 4.  Medication Nonadherence, "Professional Subjects," and Apparent Placebo Responders: Overlapping Challenges for Medications Development.

Authors:  David J McCann; Nancy M Petry; Anders Bresell; Eva Isacsson; Ellis Wilson; Robert C Alexander
Journal:  J Clin Psychopharmacol       Date:  2015-10       Impact factor: 3.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.